Earnings ·
Barinthus Biotherapeutics plc reported a net loss of $10.6 million, or $0.26 per share, for the quarter ended June 30…
BRNSBarinthus Biotherapeutics plc.
Barinthus Biotherapeutics plc reported a net loss of $10.6 million, or $0.26 per share, for the quarter ended June 30, 2026, compared to a $5.5 million loss in the prior quarter. Cash and equivalents decreased to $59.6 million from $67.2 million due to $8.1 million in operating cash usage. The company announced the completion of enrollment for all cohorts in the Phase 1 AVALON trial evaluating VTP-1000 for celiac disease, with topline data expected in Q4 2026. Barinthus Bio also disclosed that Nasdaq granted an extension until December 28, 2026, to regain compliance with listing requirements, resulting in the transfer of its ADSs from the Nasdaq Global Market to the Nasdaq Capital Market effective July 2, 2026. The company is advancing a proposed merger with Clywedog Therapeutics Inc., expected to close in H2 2026. Barinthus Biotherapeutics plc operates as a clinical-stage biopharmaceutical company focused on developing immunotherapeutic drug candidates for autoimmune and inflammatory diseases.